Canadian Stroke Best Practice Recommendations: Hyperacute Stroke Care Guidelines, Update 2015 by Leanne K Casaubon et al.
Canadian Stroke Best Practice Recommendations: Hyperacute Stroke Care
Guidelines, Update 2015
Leanne K. Casaubon1,2, Jean-Martin Boulanger3,4, Dylan Blacquiere5, Scott Boucher6,
Kyla Brown7, Tom Goddard8,9, Jacqueline Gordon10, Myles Horton11, Jeffrey Lalonde12,
Christian LaRivière13, Pascale Lavoie14, Paul Leslie15, Jeanne McNeill10, Bijoy K. Menon16,
Brian Moses17, Melanie Penn18, Jeff Perry19,20, Elizabeth Snieder20, Dawn Tymianski1,2,
Norine Foley21, Eric E. Smith16, Gord Gubitz7,8, Michael D. Hill16, Ev Glasser22, and
Patrice Lindsay2,22* on behalf of the Heart and Stroke Foundation of Canada Canadian
Stroke Best Practices Advisory Committee
The 2015 update of the Canadian Stroke Best Practice Recom-
mendations Hyperacute Stroke Care guideline highlights key
elements involved in the initial assessment, stabilization, and
treatment of patients with transient ischemic attack (TIA), isch-
emic stroke, intracerebral hemorrhage, subarachnoid hemor-
rhage, and acute venous sinus thrombosis. The most notable
change in this 5th edition is the addition of new recommen-
dations for the use of endovascular therapy for patients with
acute ischemic stroke and proximal intracranial arterial occlu-
sion. This includes an overview of the infrastructure and
resources required for stroke centers that will provide endo-
vascular therapy as well as regional structures needed to
ensure that all patients with acute ischemic stroke that are
eligible for endovascular therapy will be able to access this
newly approved therapy; recommendations for hyperacute
brain and enhanced vascular imaging using computed tomog-
raphy angiography and computed tomography perfusion;
patient selection criteria based on the five trials of endovas-
cular therapy published in early 2015, and performance metric
targets for important time-points involved in endovascular
therapy, including computed tomography-to-groin puncture
and computed tomography-to-reperfusion times. Other
updates in this guideline include recommendations for
improved time efficiencies for all aspects of hyperacute stroke
care with a movement toward a new median target door-to-
needle time of 30 min, with the 90th percentile being 60 min.
A stronger emphasis is placed on increasing public awareness
of stroke with the recent launch of the Heart and Stroke Foun-
dation of Canada FAST signs of stroke campaign; reinforcing
the public need to seek immediate medical attention by calling
911; further engagement of paramedics in the prehospital
phase with prehospital notification to the receiving emer-
gency department, as well as the stroke team, including neu-
roradiology; updates to the triage and same-day assessment
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of patients with transient ischemic attack; updates to blood
pressure recommendations for the hyperacute phase of care
for ischemic stroke, intracerebral hemorrhage, and subarach-
noid hemorrhage. The goal of these recommendations and
supporting materials is to improve efficiencies and minimize
the absolute time lapse between stroke symptom onset and
reperfusion therapy, which in turn leads to better outcomes
and potentially shorter recovery times.
Key words: endovascular therapy, guidelines, hyperacute stroke care,
neurovascular imaging, thrombolysis
Introduction
Stroke is a burden across the globe; in Canadian hospitals, one
patient is treated every nine-minutes for a stroke or a transient
ischemic attack (TIA) (1). Stroke is also the third cause of death in
Canada and a leading cause of disability (2).
The Canadian Stroke Best Practice Recommendations (CSBPR)
are evidence-based guidelines that are updated and released every
two-years (or more frequently as necessary) (2). They address the
continuum of stroke care from stroke symptom onset through the
hyperacute period to rehabilitation and longer-term recovery.
The target audience for the CSBPRs includes all healthcare pro-
fessionals involved in the care of patients with stroke or TIA
across that continuum. The present publication addresses the
hyperacute period for stroke and is intended for all members of
the interdisciplinary healthcare team who care for stroke patients
and their families throughout this stage of care.
Hyperacute stroke care specifically refers to the key interven-
tions involved in the assessment, stabilization and treatment in
the first hours after symptom onset. This represents all prehospi-
tal and initial emergency care for TIA, ischemic stroke, intracere-
bral hemorrhage (ICH), subarachnoid hemorrhage (SAH), and
acute venous sinus thrombosis. This includes assessment, diagno-
sis with the support of early neurovascular imaging, thrombolysis
or endovascular interventions for acute ischemic stroke, emer-
gency neurosurgical procedures, and same-day TIA risk stratifi-
cation and diagnostic evaluation.
Hyperacute care is time sensitive by nature, minutes for dis-
abling stroke and hours for TIA, but specific interventions are
associated with their own individual treatment windows. Broadly
speaking, ‘hyperacute’ refers to care offered in the first 24 h after
stroke (ischemic and hemorrhagic) and the first 48 h after TIA.
The prognosis of stroke is indeed very time dependent, especially
in the hyperacute period: ‘Time is Brain’. It is estimated that for
every minute delay in treating an ischemic stroke, 1·9 million brain
cells die, 13·8 billion synapses, and 12 km of axonal fibers are lost
(3). Each hour without treatment, the brain loses as many neurons
as it does in almost 3·6 years of normal aging (3). The principal
aim of this phase of care is therefore to diagnose the stroke type, to
coordinate and execute the treatment plan as rapidly as possible,
within a coordinated system of seamless workflows.
The 2015 update of the CSBPR Hyperacute Stroke module
includes many new additions, the most important one being the
use of endovascular therapy for patients with acute ischemic
stroke and proximal arterial occlusion. The update addresses
brain and vascular imaging including computed tomography
angiography (CTA) and computed tomography perfusion (CTP)
as well as patient selection for endovascular therapy.
The present publication summarizes the recommendations for
the hyperacute period. Other up-to-date and comprehensive
CSBPR for all stages of stroke care and recovery are freely available
at www.strokebestpractices.ca (2) and in a recent publication of
the Prevention of Stroke recommendations in this journal (4).
Recommendations, detailed rationales, supporting evidence,
system implications, performance measures, as well as patient and
professional education resources are detailed on our website.
What’s new in 2015
In the 2015 update of the Hyperacute Stroke Care module, there
are several notable updates. The theme of this update is Working
Together, and so there is a strong focus on the interprofessional
teams of healthcare workers involved in the hyperacute care of
people with stroke, including paramedics, emergency department
(ED) teams, stroke teams, and radiology (including neurointer-
ventionalists), emphasizing each healthcare professional’s respon-
sibilities in the hyperacute care period.
There are two time phases that are noted in the recommenda-
tions: phase 1 includes prehospital care by paramedics and other
Emergency Medical Services (EMS) personnel; phase 2 includes
ED care. There is an updated recommendation for prehospital
notification of the ED care team by paramedics/EMS personnel
that includes detailed patient-specific information that must be
relayed in this prehospital time phase (section 2). Prenotification
is imperative to ensure that stroke teams are available when an
acute stroke patient arrives in the ED to initiate patient triage and
registration, time-sensitive investigations and treatments. An
important and bold update in this edition of the Hyperacute
Stroke Care Best Practice Recommendations is a recommenda-
tion for a shorter target door-to-needle time for medical throm-
bolysis with tissue plasminogen activator (tPA) – with a new
target median time of 30 min, with the 90th percentile being
60 min (5). This change arose after a review of published quality
improvement studies that have demonstrated improvements in
the door-to-needle time in many stroke centers internationally.
The most significant update to the 5th edition of the CSBPR
Hyperacute Stroke Care module is the addition of new recom-
mendations on the use of endovascular therapy with mechanical
thrombectomy in patients with acute ischemic stroke (section
4.3). Since late 2014, five randomized controlled trials have been
published, showing improved outcomes in patients with acute
ischemic stroke treated with endovascular therapy in addition to
tPA thrombolysis (or without tPA thrombolysis in patients in
which it is contraindicated) compared with the standard of care,
which mainly included tPA thrombolysis alone. In these recom-
mendations, there is a detailed description of the infrastructure
and human resources required for all stroke centers that will be
providing endovascular therapy services; this includes the train-
ing criteria and minimal annual experience required by neuroin-
terventionalists who perform these procedures. Additionally,
brain imaging with CT and vascular imaging with computed
tomography angiography (CTA), with or without computed
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tomography perfusion (CTP), is now recommended for all acute
stroke patients presenting within the treatment time windows
(sections 3.2 and 4.1). For endovascular therapy, all eligible
patients should be treated within a six-hour time window from
the time of stroke symptom onset (or the time the patient was last
known to be well), with select patients being treated within a
12-hour time window if they meet imaging and clinical criteria
(section 4.3, Appendices S2 and S3). There are important system
implications related to endovascular therapy and the need for
screening patients with CT brain and advanced imaging with
CTA/CTP that are noted in the Recommendations (see www
.strokebestpractices.ca). With these recommendations, it should
be recognized that the literature supporting endovascular therapy
is evolving and that further studies, including a planned meta-
analysis of the major recent trials, will guide further understand-
ing of this treatment strategy for acute ischemic stroke patients.
Guideline development methodology
The CSBPR has been developed and undergo routine review and
updates using a rigorous and transparent methodology which is
described in the CSBPR Methodology Manual (6), and available
online at www.strokebestpractices.ca. The CSBPR development
and update process follows a framework adapted from the Prac-
tice Guideline Evaluation and Adaptation Cycle (7). An interpro-
fessional group of stroke experts was convened to participate in
reviewing, drafting, and revising all recommendation statements.
These experts have extensive experience in the topic areas covered
in this hyperacute module, are considered leaders and experts in
their field, have been involved in clinical trials or publications on
the topics addressed in this module, and have experience apprais-
ing the quality of research evidence. People who have experienced
a stroke or their family members are also included as group
members and/or external reviewers. The interprofessional writing
group and reviewers included stroke neurologists, ED physicians,
neurosurgeons, radiologists, family physicians, paramedics,
nurses, stroke program managers, physiotherapists, occupational
therapists, a speech language pathologist, a social worker, and a
stroke survivor. This interprofessional approach ensures that the
perspectives and nuances of all relevant health disciplines are
considered in the development of the recommendations, and
mitigate the risk of potential or real conflicts of interest from
individual members. Other experts outside the writing group
were consulted for very specific issues such as neuroimaging.
A systematic literature search was conducted to identify
research evidence for each topic area addressed in the Hyperacute
Stroke Care module. All literature searches are conducted by indi-
viduals with expertise performing systematic literature reviews
that are not directly involved in active research or the writing
group to ensure objective selection of evidence. Literature
searches include set time frames which overlap the previous
search time frame by six-months to ensure high catchment of key
articles within that time frame. The literature searches included
all published literature up to April 15, 2015.
The writing group was provided with comprehensive evidence
tables that include summaries of all high-quality evidence iden-
tified through the literature search and appraisal process. The
writing group discussed and debated the value of the evidence
and through consensus developed a final set of proposed recom-
mendations. Through their discussions, additional research had
been identified and added to the evidence tables if consensus on
the value of the research was achieved. All recommendations were
assigned a level of evidence ranging from A to C, according to the
criteria defined in Table 1. When developing and including
‘C-Level’ recommendations, consensus was obtained among the
writing group and validated through the internal and external
review process. This level of evidence is used cautiously, and only
when there is a lack of stronger evidence for topics considered
important system drivers for stroke care (e.g. transport using
ambulance services or some screening practices). Recommenda-
tions with this level of evidence may also be made in response to
requests from a range of healthcare professionals who seek guid-
ance and direction from the experts in the absence of strong
evidence on certain topics that are faced on a regular basis. In
some sections, the expert writing group felt there was additional
information that should be included within the documentation,
but these statements did not meet the criteria to be stated as
recommendations, and therefore were included as clinical consid-
erations with the goal of providing additional guidance or clarity
in the absence of evidence.
After completion of the draft update of the recommendations,
the Hyperacute Stroke Care module underwent an internal review
by the Canadian Stroke Best Practices Advisory Committee, and
an external review by 10 Canadian and international experts in
hyperacute stroke care who were not involved in any aspects of
Table 1 Summary of criteria for levels of evidence reported in the




A Evidence from a meta-analysis of randomized
controlled trials or consistent findings from two or
more randomized controlled trials. Desirable effects
clearly outweigh undesirable effects or undesirable
effects clearly outweigh desirable effects.
B Evidence from a single randomized controlled trial or
consistent findings from two or more well-designed
nonrandomized and/or noncontrolled trials, and
large observational studies. Desirable effects
outweigh or are closely balanced with undesirable
effects or undesirable effects outweigh or are closely
balanced with desirable effects.
C Writing group consensus and/or supported by limited
research evidence. Desirable effects outweigh or are
closely balanced with undesirable effects or
undesirable effects outweigh or are closely balanced
with desirable effects, as determined by writing
group consensus. Recommendations assigned a Level
C evidence may be key system drivers supporting
other recommendations, and some may be expert
opinion based on common, new or emerging
evidence or practice patterns.
*Adapted from Guyatt et al. (8).
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the guideline development. All feedbacks were reviewed and
addressed by the writing group members and the advisory com-
mittee to ensure a balanced approach to addressing suggested
edits. All recommendations are accompanied by additional sup-
porting information, including a rationale for inclusion of the
topics, system implications to ensure the structural elements and
resources are available to achieve the recommended levels of care,
performance measures to monitor care delivery and patient out-
comes, implementation resources and a summary of the evidence
to which the recommendations were based. The detailed evidence
tables are also available online. This additional supporting infor-
mation for the recommendations included in this publication
can be found at http://www.strokebestpractices.ca/index.php/
hyperacute-stroke-management.
A unique situation presented itself as the writing group
worked through the final stages of review for these hyperacute
stroke recommendations. The results of four anticipated ran-
domized clinical trials investigating the use of endovascular
therapy for large ischemic stroke were released simultaneously
in February 2015 (9–12), and a fifth trial in April 2015 (13).
These clinical trials all had similar positive findings, resulting in
strong evidence to support the use of endovascular thrombec-
tomy for people experiencing large vessel ischemic stroke
(section 4.3). An additional multistep guideline development
and review process was undertaken to be able to confidently
include recommendations related to endovascular treatment in
this edition of the CSBPR hyperacute stroke guidelines. A sub-
group of the hyperacute writing group was convened along with
representation from the ESCAPE Canadian trial leadership and
several physician members of the Canadian Stroke Best Practices
advisory committee and the Canadian Stroke Consortium. This
group thoroughly reviewed and discussed the recent endovascu-
lar trials, and compared and contrasted differences in method-
ology, clinical process steps including imaging, thrombus
retrieval techniques, and patient outcomes. A draft set of rec-
ommendations were developed that impacted section 2 (Emer-
gency Medical System Management of Stroke), section 3
(Emergency Department Initial Assessment and Treatment), and
section 4 (Acute Ischemic Stroke Therapies). The group went
through eight rounds of review to achieve a final consensus-
based set of draft recommendations. This draft was then sent to
the larger hyperacute stroke writing group for review and input,
and subsequently to the principal investigators of all four other
trials to ensure that the recommendations reflected an accurate
interpretation of their individual trial findings, and to seek their
input on the wording of the recommendations. Feedback was
reviewed and a final draft resulted. The final draft of the entire
hyperacute module was then sent to the external international
reviewers. Feedback from all stages of review was considered and
final edits were made based on consensus between the Hyper-
acute Writing Group and the Advisory Committee, as is our
normal process.
For a more detailed description of the methodology on the
development and dissemination of the CSBPRs, please refer to
the CSBPR Overview and Methodology documentation available
on the Canadian stroke best practices website at http://www
.strokebestpractices.ca/wp-content/uploads/2014/08/CSBPR2014
_Overview_Methodology_ENG.pdf (6).
CSBPR: Hyperacute Stroke Care Update 2015
This section provides detailed recommendations for several
aspects of hyperacute stroke care. These include outpatient assess-
ment, triage and management of mild nondisabling stroke; EMS
care of stroke patients in the prehospital phase; initial assessment
and management in the ED; acute stroke treatments, including
thrombolysis and endovascular therapy (new for 2015); acute
aspirin therapy; initial management of patients with ICH; initial
management of patients with SAH; and initial evaluation of
patients for hemicraniectomy. All recommendations are assigned
a level of evidence which reflects the strength and quality of the
evidence available to support the recommendations as of April 15,
2015. For more details on the rationale for the recommendations,
health system implications, suggested performance measures,
implementation resources and detailed evidence summaries and
evidence tables, please visit http://www.strokebestpractices.ca/
index.php/hyperacute-stroke-management. For full French trans-
lation of this manuscript and the recommendations, refer to
Appendix S1.
Section 1: Outpatient Management of Nondisabling
Stroke and TIA
There is clear evidence that TIAs or minor ischemic strokes are
unstable conditions that warn of high risk of future stroke, other
vascular events, or death. The risk of recurrent stroke among
patients presenting with TIA or minor stroke is as high as 10%
within the first week of symptom onset. A systematic review by
Rothwell et al. (14) pooled the results from 18 studies published
between 1997 and 2007 to obtain estimates of risk. Overall, the
reported risk of stroke at days 2 and 7 were 3·1% and 5·2%;
however, the rates of recurrence were highly variable. Timely ini-
tiation of secondary prevention medical therapy and carotid
endarterectomy has been shown to significantly reduce the risk of
major stroke after an initial TIA or nondisabling stroke. The goal
of outpatient management of TIA and nondisabling (minor)
ischemic stroke is rapid assessment and management to reduce
the risk of a recurrent, possibly more serious, event.
Management of nondisabling stroke and TIA best practice
recommendations 2015
1.0 Patients with stroke and TIA who present to an ambulatory
setting (such as primary care or other ambulatory care setting) or
to a hospital should undergo clinical evaluation by a healthcare
professional with expertise in stroke care to determine risk for
recurrent stroke and initiate appropriate investigations and man-
agement strategies.
Note: These recommendations (Section 1) pertain to patients with
TIA or subacute, nondisabling ischemic stroke patients who are
not candidates for hyperacute treatment with tPA thrombolysis
or endovascular therapy. For patients with suspected acute
stroke that warrant hyperacute investigations to determine
eligibility for thrombolysis/endovascular therapy, refer to Hyper-
acute Stroke Care Module, Section 3 (including Section 3.2 for
Neuroimaging).
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1.1 Timing of initial assessment
1.1.1. HIGHEST risk for stroke recurrence
i. Patients who present within 48 h of a suspected
transient ischemic attack or nondisabling ischemic
stroke and with transient, fluctuating, and/or persis-
tent unilateral weakness (face, arm, and/or leg), or
speech disturbance are considered at highest risk of
recurrent stroke [Evidence Level B].
a. These highest risk patients should be immedi-
ately sent to an ED with capacity for advanced
stroke care (such as brain and vascular imaging on
site, and ideally access to tPA) [Evidence Level C].
b. Urgent brain imaging [computed tomography
(CT) or magnetic resonance imaging (MRI)] and
noninvasive vascular imaging [CTA or magnetic
resonance angiography (MRA) from arch to
vertex] should be completed without delay [Evi-
dence Level B].
c. An electrocardiogram should be completed
without delay [Evidence Level B].
ii. Patients who present within 48 h of a suspected
transient ischemic attack or nondisabling ischemic
stroke with transient, fluctuating, or persistent symp-
toms without motor weakness or speech disturbance
(e.g. with symptoms such as hemibody sensory loss, or
acute monocular visual loss, or binocular diplopia or
hemivisual loss or dysmetria) may be considered at
high risk of recurrent stroke [Evidence Level C].
a. These patients should be referred for same-day
assessment at the closest stroke prevention clinic or
ED with capacity for advanced stroke care [Evi-
dence Level B].
1.1.2. INCREASED risk for recurrent stroke
i. Patients who present between 48 h and two-weeks
from onset with symptoms of transient, fluctuating, or
persistent unilateral weakness (face, arm, and/or leg),
or speech disturbance symptoms are considered at
increased risk for recurrent stroke [Evidence Level
B].These patients should receive a comprehensive
clinical evaluation and investigations by a healthcare
professional with stroke expertise as soon as possible,
at most within 24 h of first contact with the healthcare
system [Evidence Level B] (see section 1.2).
ii. Patients who present between 48 h and two-weeks
of a suspected transient ischemic attack or nondis-
abling ischemic stroke with transient, fluctuating, or
persistent symptoms without motor weakness or
speech disturbance (e.g. with symptoms such as
hemibody sensory loss, or acute monocular visual loss,
or binocular diplopia or hemivisual loss or dysmetria)
remain at increased risk of recurrent stroke [Evidence
Level C].
a. These patients should receive a comprehensive
clinical evaluation and investigations by a health-
care professional with stroke expertise as soon as
possible, at most within two-weeks of first contact
with the healthcare system [Evidence Level B] (see
section 1.2).
1.1.3. LOWER risk for recurrent stroke
i. Patients presenting more than two-weeks following
a suspected transient ischemic attack or nondisabling
ischemic stroke, may be considered as being less
urgent, and should be seen by a neurologist or stroke
specialist for evaluation as soon as possible, generally
within one-month of symptom onset [Evidence
Level C].
ii. Patients experiencing atypical sensory symptoms
(such as patchy numbness and/or tingling) are gener-
ally considered as less urgent, and may be seen by a
healthcare professional with stroke expertise as
required [Evidence Level C].
1.2 Clinical investigations for patients with TIA who are not
being considered for acute thrombolytic or endovascular
therapy
i. All patients with suspected transient ischemic attack
or nondisabling ischemic stroke should undergo an initial
assessment that includes: brain imaging and noninvasive vas-
cular imaging of the carotid arteries [Evidence Level B].
a. Extracranial vascular imaging is recommended to
identify extracranial carotid stenosis for which
patients should be referred for possible carotid revas-
cularization [Evidence Level A].
b. CT angiography should be performed at the time
of brain CT to asses both the extracranial and intrac-
ranial circulation [Evidence Level B].
c. When performing CTA or MRA, we recommend
including extracranial and intracranial vasculature
(‘aortic arch-to-vertex’) [Evidence level C].
d. Carotid ultrasound (for extracranial vascular
imaging) and MR angiography are alternatives to
CTA, and selection should be based on immediate
availability, patient characteristics [Evidence level C].
e. CTA is recommended to allow visualization of the
intracranial circulation, posterior circulation, and the
aortic arch to identify stroke etiology. A detailed
understanding of the neurovasculature guides man-
agement decisions [Evidence level C].
ii. The following laboratory investigations should be
undertaken routinely for patients with suspected TIA or non-
disabling ischemic stroke as part of the initial evaluation:
hematology (complete blood count), electrolytes, coagula-
tion [activated partial thromboplastin time (aPTT), interna-
tional normalized ratio (INR)], renal function (creatinine,
e-glomerular filtration rate), capillary glucose level [Evidence
Level C]. (Table of Recommended laboratory tests available
online at www.strokebestpractcies.ca).
iii. All patients with suspected TIA or nondisabling isch-
emic stroke should undergo an electrocardiogram (ECG) to
assess baseline cardiac rhythm, and to provide information
regarding evidence of structural heart disease (i.e. previous
myocardial infarction, left ventricular hypertrophy) [Evi-
dence Level C].
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iv. In cases where the ECG or initial cardiac rhythm
monitoring (e.g. 24 or 48 h ECG monitoring) does not show
atrial fibrillation but a cardioembolic mechanism is sus-
pected, prolonged ECG monitoring, up to 30 days duration,
is recommended in selected patients for detection of parox-
ysmal atrial fibrillation. [Evidence Level B].
v. Echocardiogram may be considered in cases where the
stroke mechanism has not been identified [Evidence Level C].
vi. Patients with clinical evidence of ischemic stroke who
are not admitted to hospital should be assessed for functional
impairment when appropriate (e.g., cognitive evaluation,
screening for depression, screening of fitness to drive, and
functional assessments for potential rehabilitation treatment)
[Evidence Level B].
Section 2: Prehospital Emergency Medical Services
Management of Acute Stroke
Approximately two-thirds of all patients who seek acute care for
stroke in Canada arrive at the ED by ambulance. Transport by
paramedics is safer and enables patients to be triaged to appro-
priate hospitals that provide specialized stroke services without
delays. The current estimated target for transport to hospital by
paramedics is in the range of 80% of cases (15). Hyperacute stroke
is a medical emergency and optimizing out-of-hospital care
improves patient outcomes. EMS plays a critical role in out-of-
hospital (prehospital) assessment and management of suspected
stroke patients. Acute interventions such as thrombolytic therapy
are time sensitive and therefore strategies such as redirecting
ambulances to stroke centers to facilitate earlier assessment, diag-
nosis, and treatment may result in better outcomes.
Emergency medical services management best practice
recommendations 2015
2.0 Out-of-hospital patient management should be optimized to
meet the needs of suspected acute stroke patients, including rec-
ognition, management, and transport, usually done concurrently
[Evidence Level C].
2.1 ACCESS to EMS
i. Immediate contact with EMS (e.g. 911) by patients or
other members of the public is strongly recommended [Evi-
dence Level B].
ii. EMS Communications Centre: All regions should imple-
ment a dispatch process through the EMS communications
center to recognize the probable stroke signs (such as FAST –
Face, Arms, Speech, Time), potential stroke diagnosis, and
need for priority response to the scene and transport to a
hospital capable of providing services for the rapid diagnosis
and treatment of stroke [Evidence Level C].
iii. After dispatching the ambulance, the personnel at the
EMS communications center should provide pre-arrival
instructions (such as unlock door, move pets, determine
stroke symptom onset time, determine current medications)
to the patient or person reporting the stroke, in order to
expedite and optimize prehospital care [Evidence Level C].
iv. The personnel at the EMS communications center should
convey relevant information (such as symptom onset time or
time last known well, and availability of an alternate decision-
maker) to the responding paramedics while they are en route
[Evidence Level C].
2.2 Paramedic on-scene management
Note: On-scene goal is to ‘recognize and mobilize’ – it is of the
utmost importance to proceed rapidly and safely to transport these
patients as on-scene management for stroke patients is limited.
i. EMS personnel should use a standardized acute stroke
out-of-hospital diagnostic screening tool as part of on-scene
assessment [Evidence Level B]. (Table 2 Canadian Stroke Best
Practices Table of Standardized Acute Stroke Out-of-Hospital
Diagnostic Screening Tools is available online at www.stroke-
bestpractices.ca).
ii. EMS personnel should obtain information from the
patient, family members, or other witnesses about the sus-
pected stroke event (presenting symptoms, time of onset or
time of symptom recognition or time last known well,
and sequence of events), comorbid conditions, current
medications, and any formal or informal advance directives
that may influence care by EMS and in the ED [Evidence
Level C].
iii. On-scene time with suspected stroke patients should be
as short as possible; ideally 20 min or less* for patients who
present within the 4.5-hour treatment time window [Evi-
dence level C]. (* Target of 20 min based on median EMS
on-scene time data from across provinces contained in HSF
Stroke Report 2015) (16).
iv. Initial care provided by paramedics on-scene should
include blood glucose measurement [Evidence Level B].
v. Prior to transport, EMS personnel should provide
instructions to the patients’ family, including recommending
that the family/decision-maker accompany the patient to
hospital or be accessible by phone for decision-making, as
well as confirming time last known well, and providing
required information about existing health conditions,
current medications, and other information as needed [Evi-
dence Level C].
2.3 Transport of suspected stroke patents
i. Direct transport protocols must be in place to facilitate
the transfer of suspected acute stroke patients who are poten-
tially eligible for thrombolytic or endovascular therapy to the
closest and most appropriate acute care hospital capable of
providing services for the diagnosis and hyperacute treat-
ment of stroke [Evidence Level C].
ii. Direct transport protocol criteria should be based on:
a. an EMS system set up to categorize patients exhibiting
signs and symptoms of an acute stroke as a high priority
for evaluation, response, and transport [Evidence
Level C];
b. the medical stability of the patient;
c. other acute care needs of the patient;
d. the prehospital phase, including symptom duration
and anticipated transport time being 3·5 h or less for
medical thrombolytic therapy (for the 4·5 h treatment
time window) and for most patients being considered for
endovascular therapy, five-hours or less (for a six-hour
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treatment time window for most patients), though select
patients may be considered for endovascular therapy up
to 12 h based on local stroke center protocols;
e. the ED’s ability to provide acute stroke services within
a target 90th percentile for door-to-needle (i.e. arrival to
treatment) time of 60 min (upper limit) and a target
median door-to-needle time of 30 min or less (5).
iii. Patients with suspected stroke should be triaged by EMS
personnel as Canadian Triage Acuity Scale (CTAS) Level 2 in
most cases and as a CTAS Level 1 for patients with compro-
mised airway, breathing, or cardiovascular function [Evi-
dence Level B].
a. For pediatric stroke cases, patients with suspected
stroke should be triaged by EMS personnel as Pediatric
Canadian Triage Acuity Scale (P-CTAS) Level 2 in most
cases, and as a P-CTAS Level 1 for patients presenting
with severe symptoms or compromised airway, breath-
ing, or cardiovascular function [Evidence Level C].
iv. While en route to the receiving hospital with acute stroke
services, paramedics should notify the ED of the incoming
suspected acute stroke patient, providing sufficient details
such that a ‘Code Stroke’ can be activated at that time [Evi-
dence Level B].
a. Information required includes: time of stroke onset or
time of symptom recognition or time when last known
well (as accurate as possible), total symptom duration at
anticipated arrival in the ED, presenting signs and symp-
toms of stroke, Glasgow Coma Scale (GCS) score, CTAS
triage score (or P-CTAS), patient age, and expected time
of arrival at the receiving hospital.
v. Patients who are considered ineligible for time-sensitive
thrombolytic therapy or endovascular therapy should still be
transported urgently (either directly or indirectly) to the
closest hospital capable of providing services for the diagno-
sis and treatment of stroke (ED, access to neurovascular
imaging, stroke unit, and stroke expertise on site or through
Telestroke modalities) [Evidence Level C].
2.4 Hospital arrival and EMS handover to ED Staff
i. Transfer of care from paramedics to receiving hospital
personnel should occur with minimal delay; patients with
suspected hyperacute stroke who are potentially eligible for
thrombolytic therapy or endovascular therapy should receive
the highest priority in the ED triage queue [Evidence Level
B]. Refer to Hyperacute Stroke Care Module, Section 3.1 for
more information.
ii. Paramedics should provide the receiving hospital with
the following information on hospital arrival: time of stroke
onset or time of symptom recognition or time when last
known well (as accurate as possible), total symptom duration
at arrival in the ED, GCS score, CTAS triage score (or
P-CTAS), patient age, comorbidities, current medications
and medication allergies, and vital signs (including capillary
glucose) [Evidence Level C].
a. Paramedics should ensure all information noted
above is documented on the patient’s EMS record and
provided to the receiving hospital during transport with
prenotification and upon arrival to the hospital [Evidence
Level B].
Clinical considerations:
• Screening for potential stroke should be done early in the
on-scene assessment. If the stroke screen is positive, all actions
on-scene from that point should be directed at moving to the
ambulance and beginning transport. All treatments not immedi-
ately required (IVs, etc.) should wait until the patient is en route to
the hospital. Scene time is an important variable that paramedics
can control and needs to be monitored very closely. Time lost due
to inefficient scene care cannot be made up during subsequent
transport to hospital, regardless of the use of lights and sirens.
• The term ‘eligible’ for acute stroke therapies is usually defined
within regional jurisdictions. Generally it refers to acute stroke
patients within the 4·5 h time window for medical thrombolytic
therapy; however, local definitions should be clarified during
implementation of these recommendations. For endovascular
therapy, the strongest evidence for benefit is when treatment is
received within six-hours of stroke symptom onset (in some
cases, without the use of medical thrombolytic therapy).
However, select patients may be considered for endovascular
therapy up to 12 h from symptom onset, as defined by imaging
criteria and within regional jurisdictions.
• In some stroke centers, the tPA treatment time window may
extend beyond 4·5 t under the directive of a research protocol.
These factors should be taken into consideration during transport
and agreements should be in place between the provincial/
regional EMS system and the receiving hospitals.
• In regions with a specialized pediatric hospital, every attempt
should be made to transport children with symptoms of stroke to
that specialized paediatric hospital.
Section 3: Emergency Department Evaluation and
Management of Acute Stroke
Time is Brain! The goal of ED management is rapid assessment of
all patients with a suspected acute stroke.
Patients who present to hospital with suspected stroke often
also have significant physiological abnormalities and comorbidi-
ties. These can complicate the management of stroke. Signs and
symptoms that may explain the cause of the stroke or predict later
complications (such as space-occupying infarction, bleeding, or
recurrent stroke) and medical conditions such as hypertension or
the presence of a coagulopathy, will have an impact on treatment
decisions. An efficient and focused assessment is required to
understand the needs of each patient.
For patients who may be eligible for acute stroke treatments
including intravenous tPA or newer endovascular therapies, the
target is to complete rapid assessment and initiate treatment as
soon as possible. Section 3.1 identifies the aspects of assessment
and investigations that are recommended for all patients; it
further identifies which investigations can wait until thrombolysis
decisions are made and acted upon for eligible patients in order to
optimize time from stroke symptom onset to acute treatment
where possible. Particularly, ECG and chest X-ray should not be
performed before imaging or acute stroke treatments unless there
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is an acute medical condition warranting them being done
sooner. Also in Section 3.1, blood work is recommended as part of
the initial evaluation. However, awaiting results should not delay
acute stroke treatment decisions and treatment initiation, unless
there is a specific clinical reason (e.g. for a patient on warfarin, an
INR level is required). Awaiting results of renal function blood
tests [Cr and estimated glomerular filtration rate (eGFR)] should
not delay imaging with CTA in most patients with disabling
acute stroke symptoms, given consideration for ‘neurons over
nephrons’. However, in certain patients with known renal impair-
ment, awaiting results of renal function blood tests should be
weighed against the benefit of immediate CTA to identify patients
that are eligible for acute stroke treatments, including endovascu-
lar therapy.
Initial management of elevated blood pressure in acute stroke
patients remains controversial due to the lack of evidence to
clearly guide practice. At the same time, this is an area where
clinicians often seek guidance from stroke specialists. The recom-
mendations for this area emphasize caution and diligence in
monitoring and treating extremely high blood pressure in the first
hours after stroke onset.
ED evaluation and management best practice
recommendations 2015
3.0 ED evaluation and management
i. All patients presenting to an ED with suspected acute
stroke must have an immediate clinical evaluation and inves-
tigations to establish a diagnosis, rule out stroke mimics,
determine eligibility for thrombolytic therapy and endovas-
cular therapy, and develop a plan for further management,
including goals for care [Evidence Level B].
ii. Patients presenting with stroke or transient ischemic
attack should not be discharged from the ED without diag-
nostic evaluations, consideration of functional impairments,
initiation or modification of secondary prevention therapies,
and a plan for ongoing management [Evidence Level B].
3.1 Initial evaluation
i. Patients with suspected acute stroke should have a rapid
initial evaluation for airway, breathing, and circulation [Evi-
dence Level B].
ii. A neurological examination should be conducted to
determine focal neurological deficits and assess stroke sever-
ity [Evidence Level B]. A standardized stroke scale should be
used, such as the National Institutes of Health Stroke
Scale (NIHSS) or the Canadian Neurological Scale (CNS)
(Table 3.1: Screening and Assessment Tools for Acute Stroke
is available online at www.strokebestpractices.ca).
iii. Assessment in the acute phase should include heart rate
and rhythm, blood pressure, temperature, oxygen saturation,
hydration status, and presence of seizure activity [Evidence
Level B].
iv. Acute blood work should be conducted as part of the
initial evaluation [Evidence Level B]. Initial blood work
should include: electrolytes, glucose, hematology (CBC),
coagulation (INR, aPTT), creatinine, eGFR, and troponin.
(Table 3.2: Recommended Laboratory Investigations for
Acute Stroke and Transient Ischemic Attack are available
online at www.strokebestpractices.ca).
v. An electrocardiogram should be completed [Evidence
Level B].
a. Unless a patient is hemodynamically unstable, ECG
should not delay assessment for thrombolysis and endo-
vascular therapy and can be deferred until after a deci-
sion regarding acute treatment is made [Evidence
Level C].
vi. A chest X-ray should be completed when the patient has
evidence of acute heart disease or pulmonary disease [Evi-
dence Level B].
a. Unless a patient is hemodynamically unstable, chest
X-ray can be deferred until after a decision regarding
acute treatment [Evidence Level C]. It should not
delay assessment for thrombolysis and endovascular
therapy.
vii. Patient swallowing screen should be completed as early
as possible by a practitioner trained to use a validated swal-
lowing screening tool as part of initial assessment, but should
not delay decision-making regarding eligibility for acute
stroke treatments [Evidence level A]. Ideally, swallow screen-
ing should be done within 24 h of hospital arrival, including
patients that receive acute stroke treatments (intravenous tPA
and endovascular therapy) [Evidence Level C].
a. Patients should remain NPO (nil per os – no oral
intake) until swallowing screen is completed for patient
safety [Evidence Level B];
b. Oral medications should not be administered until
swallowing screen, using a validated tool, has been com-
pleted and found normal [Evidence Level B]; alternate
routes such as intravenous and rectal administration
should be considered while a patient is NPO;
c. A patient’s clinical status can change in the first
hours following a stroke or TIA; therefore, patients
should be closely monitored for changes in swallowing
ability following initial screening [Evidence level C];
d. Patients found to have abnormal swallowing ability
on screening should be referred to a healthcare profes-
sional with expertise in swallowing assessments for an
in-depth swallowing assessment [Evidence Level B].
viii. Seizure Assessment: New-onset seizures at the time of
an acute stroke, occurring either immediately before or
within 24 h of the stroke onset, should be treated using
appropriate short-acting medications (e.g. lorazepam IV) if
they are not self-limited [Evidence Level C]. Treatment may
be required before completing hyperacute investigations for
stroke, including imaging.
a. A single, self-limiting seizure occurring at the onset,
or within 24 h after an acute stroke (considered an
‘immediate’ poststroke seizure) should not be treated
with long-term anticonvulsant medications [Evidence
Level C].
b. Patients that have an immediate poststroke seizure
should be monitored for recurrent seizure activity
during routine monitoring of vital signs and
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neurological status. Recurrent seizures in patients with
ischemic stroke should be treated as per treatment rec-
ommendations for seizures in other neurological condi-
tions [Evidence Level C].
• Seizures are a common presentation with stroke in
neonates and children. Consider enhanced or
increased seizure monitoring in at-risk populations
such as neonates, children with stroke, and adults
with otherwise unexplained reduced level of con-
sciousness [Evidence Level C];
• Electroencephalogram (EEG) monitoring may be
appropriate in patients at high risk of seizures, such
as neonates and children [Evidence Level C].
c. Patients with one or more seizures in the early
(defined as occurring up to four-weeks postindex
stroke) or late (occurring beyond four-weeks) post-
stroke period should be treated as per treatment recom-
mendations for seizures in other neurological
conditions [Evidence Level C]. An EEG and other tests
to rule out precipitating factors of seizures (e.g. infec-
tions) may be warranted in these patients [Evidence
Level C].
d. Prophylactic use of anticonvulsant medications in
patients with acute stroke is not recommended [Evi-
dence Level C]. There is no evidence to support the
prophylactic use of anticonvulsant medications in
patients with acute stroke and there is some evidence to
suggest possible harm with negative effects on neural
recovery.
3.2 Neurovascular (brain and vascular) imaging
i. All patients with suspected acute stroke (i.e. presenting
within acute stroke treatment time windows) must undergo
immediate noncontrast brain CT imaging, and vascular
imaging with CTA including extracranial and intracranial
arteries to guide hyperacute care [Evidence Level A].
ii. For patients with ischemic stroke that are clinically eli-
gible for acute stroke treatments, advanced CT imaging
including CTP (to assess cerebral blood flow) and multiphase
or dynamic CTA (to assess pial collateral vessels) should be
considered as part of initial imaging; however, this must not
substantially delay decision and treatment with tPA throm-
bolysis or endovascular therapy [Evidence Level B]. Note: if
there are signs of hemorrhage on initial CT images, there is no
need to proceed to CTP imaging as part of initial imaging and
CTA should be completed based on the clinical judgment of the
treating physician.
iii. Additional imaging (brain magnetic resonance imaging
(MRI or MRA) may be considered; however, this must not
delay decision and treatment with tPA thrombolysis or endo-
vascular therapy [Evidence Level C].
3.3 Cardiovascular investigations
i. All patients with suspected TIA or ischemic stroke
should undergo an ECG to assess baseline cardiac rhythm,
and to provide information regarding evidence of structural
heart disease (i.e. previous myocardial infarction, left ven-
tricular hypertrophy) [Evidence Level C].
a. Unless a patient is hemodynamically unstable, ECG
should not delay assessment for thrombolysis and endo-
vascular therapy and can be deferred until after a
decision regarding acute treatment is made [Evidence
Level C].
ii. In cases where the ECG or initial cardiac rhythm (e.g.
24- or 48-h ECG) does not show atrial fibrillation but a
cardioembolic mechanism is suspected, prolonged ECG
monitoring, up to 30 days duration, is recommended in
selected patients for detection of paroxysmal atrial fibrilla-
tion [Evidence Level B].
iii. Perform an echocardiogram in patients where a cardiac
cause of stroke is suspected, including in young adults and
children who present with stroke, and when infectious endo-
carditis is suspected [Evidence Level C].
3.4 Acute blood pressure management
i. The ideal level of blood pressure to target in the hyper-
acute phase is unknown at this time. Pharmacological agents
and routes of administration should be chosen to avoid pre-
cipitous falls in blood pressure [Evidence Level C].
ii. Ischemic stroke patients eligible for thrombolytic
therapy: Very high blood pressure should be treated in
patients receiving thrombolytic therapy for acute ischemic
stroke as this may reduce the risk of secondary intracranial
hemorrhage (to a target of below 180/105 mmHg) [Evidence
Level B].
iii. Ischemic stroke patients not eligible for thrombolytic
therapy: Treatment of hypertension in the setting of acute
ischemic stroke should not be routinely undertaken [Evi-
dence Level C].
iv. Extreme blood pressure elevation (e.g. systolic greater
than 220 or diastolic greater than 120 mmHg) should be
treated to reduce the blood pressure by approximately 15%,
and not more than 25%, over the first 24 h, with further
gradual reduction thereafter to targets for long-term second-
ary stroke prevention [Evidence Level C].
v. Avoid rapid or excessive lowering of blood pressure as
this may exacerbate existing ischemia or may induce isch-
emia, particularly in the setting of intracranial arterial occlu-
sion or extracranial carotid or vertebral artery occlusion
[Evidence Level C].
3.5 Blood glucose abnormalities
i. All patients with suspected acute stroke should have
their blood glucose concentration checked upon arrival to the
ED (Note: For patients arriving by EMS, the capillary glucose
measured by EMS should be reviewed by the ED team for any
immediate management required) [Evidence Level B].
(Table 3.2: Recommended Laboratory Investigations for
Patients with Acute Stroke or Transient Ischemic Attack is avail-
able online at www.strokebestpractices.ca).
ii. Hypoglycemia should be corrected immediately [Evi-
dence Level B].
3.6 Additional management considerations in the ED
i. Supplemental oxygen should be provided for patients
with oxygen saturation below 95% or to maintain an oxygen
saturation level above 92% [Evidence Level C].
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a. Supplemental oxygen is not required for patients
with normal oxygen saturation levels.
ii. The use of indwelling urethral catheters should be
avoided due to the risk of urinary tract infections [Evidence
Level A].
a. If used, indwelling catheters should be assessed daily
and removed as soon as possible [Evidence Level A].
b. Fluid status and urinary retention should be assessed
as part of vital sign assessments [Evidence Level C].
c. Excellent pericare and infection prevention strategies
should be implemented to minimize risk of infections
[Evidence Level C].
iii. Temperature should be routinely monitored and treated
if above 37·5°C [Evidence Level B].
iv. For some patients, based on clinical presentation and
medical history (e.g. vasculitis), additional investigations
should be considered to guide management decisions [Evi-
dence Level B].
Section 4: Acute Ischemic Stroke Therapy
The weight of evidence from many large, international trials over
a time frame of 20 years suggests that treatment with intravenous
tPA can reduce the risk of death or disability following ischemic
stroke at three to six-months posttreatment. Since the fall of 2014,
five major clinical trials of endovascular therapy with mechanical
thrombectomy were completed, with results demonstrating sig-
nificant improvement in patient outcomes after large artery
occlusions based on the modified Rankin scale score at 90 days
posttreatment (9–13), with one trial also demonstrating
decreased mortality with endovascular therapy (10). Endovascu-
lar therapy is included as a major update in the 2015 Hyperacute
Stroke Care module, with its profound impact on patients who
suffer the most devastating ischemic strokes; patients who, if left
untreated, result in a more significant burden on the healthcare
system and family caregivers. Endovascular therapy should be
provided within comprehensive and some advanced stroke
centers which, by definition, have advanced neuroimaging capa-
bility, coordinated stroke care, specialized stroke teams, and a
stroke unit to provide appropriate care and recovery after the
hyperacute period. See Appendix S2 for Criteria for Centers Pro-
viding Acute Stroke Therapy.
Acute ischemic stroke therapy best practice recommendations
2015
4.0 Patient selection
i. All patients with disabling acute ischemic stroke must be
screened without delay by a physician with stroke expertise
(either on-site or by telemedicine/telestroke consultation) to
determine their eligibility for both medical treatment with
intravenous tPA (within 4·5 h from stroke symptom onset)
and interventional treatment with endovascular therapy
(within a six-hour window from stroke symptom onset) [Evi-
dence Level A].
ii. There is limited evidence indicating that select patients
with stroke noted upon wakening or with disabling stroke
within 12 h of stroke symptom onset (or the time since last
seen well) may benefit from endovascular therapy, depending
upon clinical and imaging criteria (as defined in Appendix
S5) [Evidence Level B].
4.1 Imaging criteria
i. Initial brain CT should be assessed using the Alberta
Stroke Program Early CT Score [ASPECTS] to identify
patients with a small-to-moderate ischemic core, represented
by an ASPECTS score of 6 or higher [Evidence Level B]. Refer
to www.aspectsinstroke.com.
a. In patients with brain CT scans showing early signs of
more extensive infarction, represented by an ASPECTS of
less than 6, the decision to treat or not treat with tPA or
endovascular therapy should be made based on the clini-
cal judgment of the treating physician [Evidence Level B].
b. If CT or MR perfusion is used, it should demonstrate
a perfusion mismatch of at least 20% and a small-to-
moderate ischemic core using ASPECTS of 6 or higher.
See Appendix S5 for definitions of CT collateral score and
CT perfusion imaging criteria.
ii. For Endovascular therapy, patients should have a proxi-
mal occlusion in the anterior circulation [Evidence Level A].
a. In addition to a proximal occlusion, it is strongly rec-
ommended that patients have either moderate-to-good
pial collaterals on CTA, or CT perfusion mismatch
between the size of the penumbra and the size of the
ischemic core [Evidence Level B]. See Appendix S4 for
define inclusion/exclusion for endovascular therapy.
4.2 Intravenous thrombolysis
i. Eligible patients are those who can receive intravenous
tPA within 4·5 h of the onset of stroke symptoms [ (17),
ECASS III] in accordance with criteria adapted from National
Institute of Neurological Disorders and Stroke (NINDS) tPA
Stroke Study (18) [Evidence Level A]. Refer to Appendix S3
for inclusion and exclusion criteria for intravenous tPA
eligibility.
a. When it is unclear whether or not a patient should be
treated with tPA, urgently consult with a stroke specialist
within the institution or through telestroke services [Evi-
dence Level C].
b. If there is uncertainty regarding CT imaging interpre-
tation, consult a radiologist in your institution [Evidence
Level C].
ii. All eligible patients should receive intravenous tPA as
soon as possible after hospital arrival [Evidence Level A], with
a target door-to-needle time of less than 60 min in 90% of
treated patients and a median door-to-needle time of 30 min
[Evidence Level B]. Treatment should be initiated as soon as
possible after patient arrival and CT scan; every effort should
be made to ensure door-to-needle times are routinely moni-
tored and improved.
a. Administration of tPA should follow the American
Stroke Association guidelines using a dose of 0·9 mg/kg
to a maximum of 90 mg total dose, with 10% (0·09 mg/
kg) given as an intravenous bolus over one-minute and
the remaining 90% (0·81 mg/kg) given as an intravenous
infusion over 60 min [Evidence Level A].
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iii. There remain situations in which clinical trial data to
support the use of intravenous thrombolytic therapy are
more limited. In these situations, urgent consultation with a
stroke expert is recommended alongside the clinical judg-
ment of the treating physician and discussion with the patient
or substitute decision maker [Evidence Level C].
a. This can apply to: pediatric stroke (newborn to age 18
years); and pregnant women with stroke.
iv. Hospital inpatients that present with a sudden onset of
new stroke symptoms should be rapidly evaluated by a spe-
cialist team and provided with access to appropriate acute
stroke treatments (including thrombolysis and endovascular
therapy) [Evidence Level B]. Management of complications
from tPA administration:
a. There is insufficient evidence to support the routine
use of fresh frozen plasma, prothrombin complex con-
centrates, or platelet transfusions for tPA-associated
bleeding [Evidence Level C].
b. For tPA-induced angioedema, discontinue the tPA
infusion if it is still running, obtain assistance for airway
management if required, and give intravenous hydrocor-
tisone 100 mg, diphenhydramine 50 mg, and ranitidine
50 mg. The use of racemic epinephrine by nebulizer
should be weighed against the risk of sudden hyperten-
sion and the risk of intracranial hemorrhage [Evidence
Level C].
4.3 Endovascular therapy
i. Endovascular therapy should be offered within a coordi-
nated system of care including agreements with EMS; access
to rapid neurovascular (brain and vascular) imaging; coordi-
nation between the ED, the stroke team and radiology; local
expertise in neurointervention; and access to a stroke unit for
ongoing management [Evidence Level A].
ii. Endovascular therapy is indicated in patients based upon
imaging selection with noncontrast CT head and CTA
(including extracranial and intracranial arteries) [Evidence
Level A]. See Appendix S4 for Inclusion Criteria for endovascu-
lar therapy.
iii. Eligible patients who can be treated within six-hours (i.e.
whose groin can be punctured within six-hours of symptom
onset) should receive endovascular therapy [Evidence Level
A]. Refer to Appendix S4 for Inclusion Criteria for endovascular
therapy.
a. Select patients with disabling stroke presenting
between 6 and 12 h of stroke symptom onset, including
those with stroke symptoms upon awakening, who meet
clinical and imaging criteria, may be considered for endo-
vascular therapy [Evidence Level B], in accordance with
local protocols.
b. Time from CT (first slice of the noncontrast CT) to
groin puncture should be as fast as possible, ideally less
than 60 min [Evidence Level C].
iv. Endovascular therapy is indicated in patients who have
received intravenous tPA and those who are not eligible for
intravenous tPA [Evidence Level A]. Patients eligible for
intravenous tPA as well as endovascular therapy should also
be treated with intravenous tPA, which can be initiated while
simultaneously preparing the angiography suite for endovas-
cular therapy [Evidence Level A].
v. Device selection: Retrievable stents are recommended as
the first-choice endovascular device [Evidence Level A].
a. Other interventional devices (e.g. thrombus aspira-
tion devices) may be used based on local protocols and
expertise [Evidence Level C].
vi. Endovascular procedures should not be performed using
elective general anesthesia and intubation in most patients.
General anesthesia and intubation should only be used if
medically indicated (e.g. for airway compromise, respiratory
distress, depressed level of consciousness, severe agitation, or
any other indication determined by the treating physician),
and in such cases, excessive and prolonged hypotension
should be avoided [Evidence Level B].
Clinical considerations for acute ischemic stroke therapies:
• Intravenous tPA is considered the standard of care and is cur-
rently the only approved thrombolytic agent for acute ischemic
stroke treatment. There are other drugs being investigated; how-
ever, at this time they are not approved for use in stroke patients.
• The 2012 IST3 trial (19) suggests that in some patients, it is safe
to administer intravenous tPA up to six-hours from time last
known well. At this time, the evidence is not strong enough to
extend recommended treatment times for tPA beyond 4·5 h for
intravenous therapy.
• tPA administration for patients on direct oral anticoagulants
(DOACs): until such time when there is a commercially available
and validated assessment tool for DOAC levels, and until such
time as it is reliably known what these levels mean clinically, tPA
should not routinely be administered to patients on DOACs pre-
senting with acute ischemic stroke. Endovascular therapy may be
considered in such patients.
• Large artery occlusions in the posterior circulation (e.g. basilar
artery occlusion) may be considered for endovascular therapy
based on the clinical judgment of a treating physician with stroke
or neurointerventional expertise. It should be noted that these
patients were excluded from recent trials of endovascular therapy.
Section 5: Acute Aspirin Therapy
Acute-phase aspirin therapy reduces the risk of early recurrent
ischemic stroke (20). Long-term aspirin therapy reduces the risk
of ischemic stroke, myocardial infarction, and vascular death.
There is a paucity of data from randomized controlled trials to
support the use of other antiplatelet regimes in acute stroke
patients. In clinical trials for tPA, antithrombotic drugs (including
aspirin) were avoided until after the 24-hour post-thrombolysis
scan had excluded intracranial hemorrhage.
Acute aspirin therapy best practice recommendations 2015
All acute stroke patients not already on an antiplatelet agent and
not receiving tPA therapy should be given at least 160 mg of
acetylsalicylic acid (ASA) immediately as a one-time loading dose
after brain imaging has excluded intracranial hemorrhage and
after dysphagia screening has been performed and passed [Evi-
dence Level A].
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i. In patients treated with tPA, acetylsalicylic acid (ASA) should
be delayed until after the 24-hour post-thrombolysis scan has
excluded intracranial hemorrhage [Evidence Level B].
ii. ASA (81 to 325 mg daily) should then be continued indefi-
nitely or until an alternative antithrombotic regime is started
[Evidence Level A]. Refer to Canadian Stroke Best Practice Recom-
mendations Prevention of Stroke Module Sections 6 and 7 for addi-
tional information.
iii. In dysphagic patients, ASA may be given by enteral tube
(80 mg daily) or by rectal suppository (325 mg daily) [Evidence
Level A].
iv. In pediatric patients, initial treatment with anticoagulation
(heparin) or aspirin at established pediatric dosing should be
considered and continued until cervical artery dissection and
intracardiac thrombus is excluded. If neither is present, switch to
acute aspirin therapy at dose of 1–5 mg/kg [Evidence Level B]
(21).
v. In patients already on ASA prior to ischemic stroke or transient
ischemic attack, clopidogrel may be considered as an alternative
[Evidence Level B]. If rapid action is required, then a loading dose
of 300 mg of clopidogrel could be considered, followed by a main-
tenance dose of 75 mg once a day [Evidence Level B].
Section 6: Acute Subarachnoid Hemorrhage
SAH is a catastrophic neurosurgical emergency that is prevalent
in approximately 7% of adults with stroke (1), and also in chil-
dren, and accounts for prolonged hospital lengths of stay. Recent
mortality rates in Canada for patients with SAH are just over 40%
within 30 days of the event. Over the past decade, several advances
have been made in early treatment of SAH, including endovascu-
lar techniques. Prompt recognition and access to expert medical
professionals may reduce mortality and morbidity and improve
long-term outcomes. These recommendations focus on diagnosis
and early management of SAH patients in the first hours after
symptom onset. Blood pressure management, temperature, risk
of venous thromboembolism and vasospasm should all be
addressed in caring for patients with SAH.
Acute SAH best practice recommendations 2015
6.0 Patients with aneurysmal SAH should be treated as a medical
emergency and evaluated immediately by physicians with exper-
tise in stroke management [Evidence Level B].
6.1 Consultation with neurosurgery for patients with SAH
i. There is a high early risk for rebleeding in SAH patients;
therefore they should be assessed without delay [Evidence
Level B].Patients with SAH should have an urgent consulta-
tion with a neurosurgeon [Evidence Level B].
ii. Patients should be managed in centers with neurosurgi-
cal expertise that treat aneurysms regularly using endovascu-
lar and surgical techniques [Evidence Level C].
6.2 Initial clinical assessment of a patient with SAH
i. Patients with suspected SAH should have a noncontrast
CT scan immediately on arrival to hospital to confirm the
diagnosis [Evidence Level B].
ii. In patients with a new acute headache suspicious of
SAH, a third-generation or higher* CT scan performed
within six-hours of onset of headache and read as normal by
a neuroradiologist; a lumbar puncture is not required
[Evidence Level B].
a. If there is a high clinical index of suspicion of SAH
and no availability of an experienced neuroradiologist
to review the CT imaging, then a lumbar puncture and
cerebral spinal fluid (CSF) analysis should be performed
[Evidence Level C].
iii. If a lower generation CT scan is done and read as
normal, and the clinical suspicion of SAH is high, or if the CT
is performed after six-hours, or is not read by an experienced
radiologist or the patient is in an altered state of conscious-
ness, a lumbar puncture should be performed.
a. Xanthochromia evaluation may be more sensitive
after a minimum delay of 12 h from onset of headache,
but such a delay may not be practical or clinically appro-
priate [Evidence Level B].
iv. Patients with SAH should undergo vascular imaging of
the brain to investigate the cause of the hemorrhage. High-
quality CTA may be initially preferable to catheter angiogra-
phy [Evidence Level B], but catheter angiography should
still be considered as the ‘gold standard’ when initial CTA is
negative.
v. The severity of SAH patients should be determined
using a validated scale [Evidence Level B].
vi. Recommended assessment tools may include: World
Federation of Neurological Surgeons (WFNS), GCS, Hunt
and Hess scale (H&H), NIHSS, and the Fisher Scale. Other
tools may be considered as appropriate to individual patients.
6.3 Interventions for patients with SAH
i. Once a SAH is confirmed, patients initially seen in non-
comprehensive stroke centers should be transferred to a ter-
tiary center for ongoing management [Evidence Level C].
ii. Patients with SAH and negative noninvasive vascular
imaging should be considered for further imaging with cath-
eter angiography [Evidence Level C].
iii. Patients who present within 96 h of a SAH and have an
adequate blood pressure should immediately be started on
nimodipine for 14 to 21 days [Evidence Level A]. Refer to
local protocols for usual dosing schedules.
iv. Patients with an aneurysmal SAH should have the aneu-
rysm secured urgently by endovascular coiling or microsur-
gical clipping, ideally within 24 to 48 h [Evidence Level B].
v. Patients with aneurysmal SAH and CT evidence of
hydrocephalus that is clinically symptomatic should undergo
urgent placement of an external ventricular drain (EVD)
[Evidence Level B].
vi. For SAH patients with decreased level of consciousness
(LOC) and large intraparenchymal extension at the time the
aneurysm is secured, urgent evacuation of the hematoma
should be considered [Evidence Level C].
vii. For most patients with SAH who are technically eligible
for endovascular or microsurgery treatment, an endovascular
approach is preferred (ISAT trial) [Evidence Level A].
a. Decisions regarding modality of treatment should be
based on patient-specific characteristics, which include
consideration of patient age, clinical grade, size, location
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and morphology of the aneurysm, medical comorbidity,
and institutional experience and resources [Evidence
Level B].
viii. In the absence of seizures, routine use of prophylactic
anti-convulsants is not recommended [Evidence Level B].
6.4 Blood pressure management
i. Patients with an unsecured aneurysm in a SAH should
have their blood pressure closely monitored and maintained
as normotensive [Evidence Level B].
ii. Treatment for high blood pressure should be initiated
while the aneurysm is unsecured to reduce the risk of
hypertension-induced rebleeding and maintain cerebral per-
fusion pressure [Evidence Level B].
6.5 Additional aspects of clinical management
i. Neurological assessment should be conducted as part of
regular vital signs, using standardized assessment tools
throughout the course of stay to monitor changes, and ideally
every one to four-hours until patient is stable as per local
protocols [Evidence Level C].
a. Frequency of neurological assessment should be
adjusted according to patient’s condition (e.g. frequency
may increase during episodes of vasospasm);
ii. Patients with SAH should have the head of their bed
elevated 30 degrees for at least the first 24 to 48 h [Evidence
Level B].
iii. Elevated temperature should be treated to achieve nor-
mothermia in SAH patients [Evidence Level B]. Refer to
Canadian Stroke Best Practice Recommendations Acute
Inpatient Stroke Care module section 4.2 for additional
information.
iv. Patients with SAH should receive venous thromboem-
bolism prophylaxis [Evidence Level A]. Refer to Canadian
Stroke Best Practice Recommendations Acute Inpatient Stroke
Care module section 2.2 for additional information.
a. Sequential compression devices are recommended in
the early stages prior to having the aneurysm secured
[Evidence Level B]. Refer to Canadian Stroke Best Prac-
tice Recommendations Acute Inpatient Stroke Care
module section 2.2 for additional information.
v. For patients with poor prognosis for neurological recov-
ery, an initial course of supportive nonsurgical management
may be appropriate [Evidence Level B].
a. Goals of care should be established early after patient
arrival at hospital, with patient and/or designated sub-
stitute decision-maker [Evidence Level B];
b. Patients who are given Do Not Resuscitate (DNR)
status at any point should receive all other appropriate
medical and surgical interventions unless otherwise
explicitly indicated. Preexisting DNR orders should be
considered where appropriate [Evidence Level C].
vi. There is insufficient evidence to support routine admin-
istration of high-dose magnesium during the acute stage of
SAH [Evidence Level C].
vii. Patients with SAH should not be routinely started on
statin therapy during the acute stage if not already on a statin
prior to admission [Evidence Level A].
6.6 Vasospasm: symptomatic vasospasm is an acute ischemic
event that requires acute treatment. Note: Vasospasm most com-
monly occurs after the hyperacute period, but is addressed here as
part of comprehensive coverage of issues related to SAH.
i. Hypovolemia should be avoided after SAH [Evidence
Level B].
ii. The maintenance of euvolemia, instead of hyperv-
olemia, is recommended to prevent or treat symptomatic
vasospasm [Evidence Level B].
iii. Prophylactic treatment of vasospasm with hyperdy-
namic therapy or balloon angioplasty is not recommended
[Evidence Level B].
iv. With the absence of cardiac contraindication and after
the treatment of the ruptured aneurysm, patients with symp-
tomatic vasospasm should first be treated with induced
hypertension (blood pressure target according to neurologi-
cal response). [Evidence Level C].
v. Mechanical or chemical endovascular treatment can be
used in patients with symptomatic vasospasm having con-
traindication or being refractory to induced hypertension
[Evidence Level C].
Section 7: Acute Intracerebral Hemorrhage
ICH is the most fatal form of stroke and carries the poorest
prognosis for survival and functional recovery. ICH commonly
occurs in about 12–15% of all stroke patients admitted to Cana-
dian hospitals (1), and is associated with high rates of early mor-
tality – 25–50% in the first 30 days (1). Patients who survive an
ICH are often left with moderate to severe persistent functional
deficits which place a significant burden on families and the
healthcare system. Therefore, this condition requires prompt rec-
ognition and action. Efficient clinical assessment, blood pressure
and coagulopathy management, and access to neurosurgery are all
important aspects of hyperacute care. While baseline hematoma
volume is a strong predictor of outcome, it is not a modifiable risk
factor. In addition, 30–40% of patients will continue to bleed and
experience hematoma expansion, which is also a predictor of
poor outcome. Risk factors for hematoma expansion may include
the presence of a ‘spot sign’ (i.e. contrast extravasation), early
presentation to medical attention, anticoagulation use, and initial
hematoma volume (22). These recommendations are for patients
with primary spontaneous ICH, not hemorrhagic conversion of
an ischemic infarction, and apply to the initial assessment in the
ED within the first few hours of patient arrival. Ongoing treatment
and management of hemorrhagic stroke patients beyond the initial
hyperacute period is outside the scope of these recommendations.
Acute ICH best practice recommendations 2015
7.0 Patients with ICH must be treated as a medical emergency.
ICH should be promptly recognized and patients evaluated
immediately by physicians with expertise in hyperacute stroke
management.
7.1 Initial clinical assessment of an ICH patient
i. An NIHSS should be conducted on awake or drowsy
patients, or a GCS on patients who are obtunded, semi or
fully comatose, as part of initial assessment to determine
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baseline severity of neurological impairments [Evidence
Level B]. This has been found to be a strong predictor of
outcomes following ICH.
ii. Patients with suspected ICH should undergo a CT or
MRI immediately to confirm diagnosis, location, and extent
of hemorrhage [Evidence Level A].
iii. In patients with confirmed acute ICH, CT angiography,
MR angiography, or catheter angiography is recommended
for most patients to exclude an underlying lesion such as an
aneurysm or arteriovenous malformation [Evidence Level B].
iv. Evaluation of patients with acute ICH should include
questions about anticoagulant therapy, measurement of
platelet count, partial thromboplastin time (PTT), and INR
[Evidence Level A], and medication history [Evidence
Level C].
v. Patients should be assessed for clinical signs of increased
intracranial pressure [Evidence Level B].
vi. A validated neurological scale, such as CNS score,
should be conducted (usually by nurses) at baseline and
repeated at least hourly for the first 24 h, depending on sta-
bility of patient [Evidence Level C].
7.2 Blood pressure management
i. Blood pressure should be assessed on initial arrival to
the ED and every 15 min thereafter until it has stabilized
[Evidence Level C].
ii. Blood pressure targets in ICH patients may be challeng-
ing to achieve and require careful monitoring, and in some
cases aggressive repeated dosing or intravenous infusion of
antihypertensive medications [Evidence Level C].
iii. Close blood pressure monitoring (e.g. every 30 to
60 min, or more frequently if above target) should continue
for at least the first 24 to 48 h [Evidence Level B].
iv. There is presently insufficient evidence to demonstrate
that lower blood pressure targets are associated with better
clinical outcomes, and research is ongoing in this area.
However, there is evidence to support safety for a target sys-
tolic blood pressure less than 140 mmHg [Evidence Level B].
v. Labetalol is recommended as a first-line treatment for
acute blood pressure management if there are no contraindi-
cations [Evidence Level B].
vi. After the first 24 h following the onset of an ICH,
further blood pressure lowering should be continued with the
initiation of parenteral or oral antihypertensive medications
(depending on swallowing ability), to achieve individualized
blood pressure targets that will optimize secondary stroke
prevention [Evidence Level B].
7.3 Management of anticoagulation
i. Patients with acute ICH and an established coagulopa-
thy or a history of anticoagulation medications should be
promptly assessed with laboratory tests (INR/PTT) and have
a medical treatment plan to control bleeding [Evidence
Level B].
ii. Warfarin use with an elevated INR should be treated
appropriately to reverse the coagulopathy with prothrombin
complex concentrate (PCC) and vitamin K. PCC is preferred
because the onset of action is fast, but fresh-frozen plasma
and vitamin K could be used as alternative if PCC is not
available [Evidence Level B].
iii. Antiplatelet agents (e.g. ASA, clopidogrel, dipyridamole/
ASA) should be stopped immediately in patients who present
who are routinely on these agents [Evidence Level C].
iv. DOAC use requires urgent consultation with a hema-
tologist regarding use and availability of reversal agents [Evi-
dence Level C].
v. If there is a persisting strong indication for anticoagu-
lation (e.g. atrial fibrillation, mechanical heart valve), the
decision about when to restart anticoagulant therapy should
be made on a case-by-case basis [Evidence Level C].
vi. The evidence is unclear regarding timing to restart anti-
coagulation. Consultation with a stroke expert, cardiologist,
hematologist/thrombosis expert may be considered to opti-
mize individual patient care [Evidence Level C].
7.4 Consultation with neurosurgery
i. Patients with cerebellar hemorrhage should be referred
for urgent neurosurgical consultation, particularly in the
setting of altered level of consciousness or new brainstem
symptoms [Evidence Level C].
ii. Patients with new onset of acute hydrocephalus requir-
ing placement of EVD should be referred for urgent neuro-
surgical consultation [Evidence Level C].
iii. Surgical intervention has not been shown to be superior
to conservative management to improve outcomes in most
patients with supratentorial ICH [Evidence Level B]. In select
patients with a higher level of consciousness (especially GCS
score 9–12), early surgical intervention may be considered
[Evidence Level B].
iv. Early consultation with a neurosurgeon is recom-
mended in cases where decompressive craniectomy is
considered [Evidence Level C]. Refer to Section 8 on Hemi-
craniectomy for additional information.
7.5 Initial interventions for ICH patients
i. Medically stable patients with an acute ICH should be
admitted to a stroke unit or neuro-intensive care unit [Evi-
dence Level B], and undergo interprofessional stroke team
assessment to determine their rehabilitation and other care
needs.
ii. Administration of recombinant Factor VIIa (NiaStase)
prevents hematoma growth, but increases the risk of arterial
thromboembolic phenomena and does not provide a clinical
benefit for survival or outcome. It is not recommended for
use outside of clinical trials at this time, and clinical trials
are currently ongoing to address this issue [Evidence
Level A].
iii. Statin therapy is not indicated for prevention of ICH.
For ICH patients who have a clear concomitant indication for
cholesterol lowering treatment, statin therapy should be indi-
vidualized and should take into account the patient’s overall
thrombotic risk as well as the possibility of increased risk of
ICH on statin therapy [Evidence Level B].
iv. Beyond the acutely symptomatic period, patients with
ICH should be managed similarly to those with ischemic
stroke, except for avoidance of antithrombotic medications
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[Evidence Level B]. Refer to recommendation 7.3 for addi-
tional information.
v. Goals of care should be established with patient and/or
designated substitute decision-maker [Evidence Level B].
vi. For most patients, decisions related to DNR orders or
palliative care should be deferred for 24 to 48 h after stroke
onset, to allow time to see if there is a significant response to
medical therapy or if there is worsening [Evidence Level C].
a. Exceptions may include patients with preexisting
wishes to avoid invasive life-sustaining therapies
because of comorbidities (e.g. dementia) or based on
their own previously expressed values [Evidence
Level C].
vii. Patients who are given DNR status at any point should
receive all other appropriate medical and surgical interven-
tions unless otherwise explicitly indicated. Preexisting DNR
orders should also be reassessed after 24 to 48 h [Evidence
Level C].
viii. Currently there is no role for prophylactic anti-
convulsant treatment [Evidence Level C]. If a patient were to
present with or proceed to have a seizure, anti-convulsants
should be initiated.
Section 8: Early Management of Patients Considered
for Hemicraniectomy
The morbidity and mortality for the routine care of patients with
malignant hemispheric strokes is higher than other stroke sub-
groups and there is evidence to support that, in selected cases,
hemicraniectomy may significantly reduce mortality and lead to
improvement in patient outcomes. Consideration for hemi-
craniectomy must be individualized; there is a strong need for
careful clinical consideration and patient selection. Decisions
regarding hemicraniectomy involve several members of the inter-
professional team, including neurology, neurosurgery, intensive
care, and nursing through a collaborative and coordinated system
of care. The benefit of decompressive hemicraniectomy (vs. stan-
dard medical treatment) early following malignant middle cere-
bral artery (MCA) infarction in patients <60 years has been
evaluated in three major randomized controlled trials, all of
which had comparable inclusion criteria and primary outcome
measures (23–25). Timing of surgical intervention is also an
important consideration when deciding whether to perform
decompressive hemicraniectomy. Taken together, these findings
suggest that the appropriate time interval to perform decompres-
sive hemicraniectomy may be within 48 h of stroke symptom
onset; further research is needed to determine if earlier treatment
(e.g. within 24 h) is associated with superior outcomes.
Early management of patients considered for
hemicraniectomy best practice recommendations 2015
8.0 Hemicraniectomy should be considered in younger patients
in the early stages of extensive (malignant) MCA territory isch-
emic stroke [Evidence Level A].
8.1 Patient selection
i. Patients who meet the following criteria alone or in
combination should be considered for hemicraniectomy
[Evidence Level A]:
a. Patients over the age of 18;
b. Children under 18 years with progressive extensive
(malignant) MCA syndrome [Evidence Level C];
c. Extensive (malignant) MCA territory ischemic
stroke with evidence of edema/mass effect;
d. Infarction size greater than 50% MCA territory on
visual inspection, or an ischemic lesion volume greater
than 150 cm3;
e. Worsening NIHSS score, CNS score, GCS, or the
Pediatric NIHSS scores, or imaging indications of wors-
ening edema at any time from presentation.
ii. If patient location is initially outside a comprehensive
stroke center, patient should have expedited transfer to a
tertiary or quaternary center where advanced stroke
care and neurosurgical services are available [Evidence
Level C].
8.2 Initial clinical evaluation
i. Urgent consultation with a stroke specialist for assess-
ment and for determination to involve neurosurgery [Evi-
dence Level C]
ii. For patients who meet criteria for potential hemi-
craniectomy during initial assessment, an urgent neurosurgi-
cal consultation should be initiated, either in-person or via
telemedicine (Telestroke services) [Evidence Level C].
iii. Initiate a discussion with patient, family members, and
legal decision-maker regarding a potential hemicraniectomy
[Evidence Level C].
a. Key issues to be discussed with decision-makers
include: stroke diagnosis and prognosis untreated, the
risks of surgery, the possible and likely outcomes follow-
ing surgery, and the patient’s previously expressed
wishes concerning treatment in the event of catastrophic
illness.
8.3 Patient management prior to hemicraniectomy surgery
i. Once decision for hemicraniectomy has been con-
firmed, surgery should take place within 48 h of initial pre-
sentation [Evidence Level A], and surgery should take
place before major midline shift occurs [Evidence
Level C].
ii. Patients should be transferred to an intensive care unit
or neuro step-down unit for close and frequent monitoring of
neurological status prior to surgery [Evidence Level B].
a. Monitoring should include assessments of level of
consciousness (e.g. CNS score), worsening symptom
severity, and blood pressure at least hourly; more fre-
quently as the individual patient condition requires
[Evidence Level C].
b. If changes in status occur, the stroke team and neu-
rosurgeon should be notified immediately for reevalua-
tion of the patient [Evidence Level C]. Change in
status may include increasing level of drowsiness/
consciousness, drop in CNS score by 1 point, or increase
in NIHSS score by 4 points.
c. Repeat CT scans are recommended for patients when
deterioration in neurological status occurs [Evidence
Level C].
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iii. Determine need for acute blood pressure treatment for
high blood pressure [Evidence Level B]. Refer to Recommen-
dation 3.4 in this Module for additional information.
iv. Hyperosmotic therapy with 20% mannitol or 3% hyper-
tonic saline may be used in the perioperative period if
required [Evidence Level C].
v. The head of the patient’s bed should be elevated 30°
[Evidence Level C], and patient and family members should
be educated about proper head positioning [Evidence
Level C].
vi. In general, hyperventilation should be avoided prior to
surgery [Evidence Level C].
vii. All antiplatelets and anticoagulants should be withheld
prior to hemicraniectomy [Evidence Level B].
viii. Corticosteroids are not recommended as a management
strategy for increased intracranial pressure for patients await-
ing hemicraniectomy [Evidence Level A].
ix. If hydrocephalus occurs, it may be managed by an EVD
placed by a neurosurgeon [Evidence Level C].
Summary
The 2015 update of the Canadian Stroke Best Practice Hyperacute
Stroke Care Recommendations provide a common set of guiding
principles and evidence-based actions from the first signs of
stroke onset through to the end of ED care. The quality of recov-
ery and outcomes for people with acute stroke is highly depen-
dent on this hyperacute period. There is an absolute need for
prompt recognition of stroke signs, contact with EMS, and access
to care by specialized stroke teams with advanced imaging and
intervention capability. Access to this care is challenging in a
country such as Canada, with a vast geography and with a larger
proportion of rural and remote communities. Coordinated
systems of care have been established in many provinces which
include bypass protocols for paramedics and the use of Telestroke
modalities to access specialists at large urban centers for consul-
tation and to support intravenous tPA administration. The strong
evidence that has emerged for endovascular therapy to treat
patients with large artery occlusions will necessitate a review of
the existing stroke systems to ensure that endovascular centers are
established to service as many regions as possible. This will take
time; however, the magnitude of effect that these therapies have
on the recovery of patients who would otherwise likely die or be
more severely disabled and requiring intensive levels of long-term
care, makes access to these therapies an imperative.
The CSBPRs are developed and presented within a continuous
improvement model and are written for health system planners,
funders, administrators, and healthcare professionals, all of whom
have important roles in the optimization of stroke prevention and
care and who are accountable for results. Several implementation
tools are provided to facilitate uptake into practice (available at
www.strokebestpractices.ca), and are used in combination with
active professional development programs. By monitoring perfor-
mance, the impact of adherence to best practices is assessed and
results are then used to direct ongoing improvement. Tracking the
uptake and outcomes of the newer endovascular therapies will
require consensus on case definitions, intervention codes, and key
indicators such as treatment times and primary outcomes. Recent
stroke quality monitoring activities have shown compelling
results with a relative decrease in 30-day in-hospital mortality of
over 30% in the past decade (2), which continues to support the
value of adopting evidence-based best practices in organizing and
delivering stroke care in Canada.
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